(Q38124394)

29 August 2017

Neuronal toxicity of efavirenz: a systematic review (English)

1 reference

29 August 2017

1 reference

1 reference

Eric H Decloedt

1

0 references

Gary Maartens

object named as

Gary Maartens

series ordinal

2

0 references

language of work or name

English

0 references

publication date

29 July 2013

1 reference

Expert Opinion on Drug Safety

29 August 2017

1 reference

29 August 2017

12

1 reference

29 August 2017

6

1 reference

29 August 2017

841-846

1 reference

A systematic review of the psychiatric side-effects of efavirenz

29 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Implications of efavirenz for neuropsychiatry: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Neuropsychiatric complications of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Efavirenz-induced psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Efavirenz-induced psychosis leading to involuntary detention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Manic syndrome associated with efavirenz overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

A manic episode associated with efavirenz therapy for HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Severe efavirenz-induced vacuolar axonopathy complicated by fatal aspiration pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Higher efavirenz plasma levels correlate with development of insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Drug uptake transporters in antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Drug interactions at the blood-brain barrier: fact or fantasy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

ABCB1 4036A>G and 1236C>T Polymorphisms Affect Plasma Efavirenz Levels in South African HIV/AIDS Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Antiretroviral neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Impaired brain creatine kinase activity in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Brain aging, Alzheimer's disease, and mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Efavirenz induces depressive-like behaviour, increased stress response and changes in the immune response in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Cytokine targets in the brain: impact on neurotransmitters and neurocircuits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Antiretroviral drugs and the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Clinical implications of CNS penetration of antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.823396

10.1517/14740338.2013.823396

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference

PubMed ID

23889591